This chart shows the yearly performance of the chosen ETF to key asset classes of Aussie shares (ASX: VAS) and US shares (ASX: IVV). You can use this chart to visualise how the ETF responds to different market environments. We recommend using a 5+ year time horizon for comparisons. The chart compares price return only.
The ETFS S&P Biotech ETF (ASX:CURE) is one of the more novel ETFs on the ASX but it has got off to healthy start (pun intended). Below, I’ll list some of the strengths and risks for CURE.
The historical benefit of low-cost index investing in Australian shares covered by the ASX 200 (INDEXASX: XJO) is obvious.
If you want to add growth shares your investment portfolio but you’re not comfortable picking individual shares, consider adding the ASX ETFs I’ve outlined below.
The Integrated Research Limited (ASX: IRI) share price crumbled 13% this morning despite releasing a promising update to ASX investors.
The AMP Limited (ASX:AMP) share price fell 8% today following news that it may scrap its interim dividend to shareholders with uncertainty over the Resolution Life takeover of its Life business.
The ETFS S&P Biotech ETF (ASX:CURE) is one of the more novel ETFs on the ASX but it has got off to healthy start (pun intended). Below, I’ll list some of the strengths and risks for CURE.
The historical benefit of low-cost index investing in Australian shares covered by the ASX 200 (INDEXASX: XJO) is obvious.
If you want to add growth shares your investment portfolio but you’re not comfortable picking individual shares, consider adding the ASX ETFs I’ve outlined below.
The Integrated Research Limited (ASX: IRI) share price crumbled 13% this morning despite releasing a promising update to ASX investors.
The AMP Limited (ASX:AMP) share price fell 8% today following news that it may scrap its interim dividend to shareholders with uncertainty over the Resolution Life takeover of its Life business.
Right now, there are 200+ ETFs on the ASX. Then there are index funds. Hundreds of managed funds. LICs. REITs. And everything in between. Wouldn’t it be nice to make ONE investment and build the strong Core of your portfolio — with just one click?
Rask’s lead ETF research analyst and investing team have identified our #1 ETF for 2021 and beyond. Our analyst team has put together a full research report and a step-by-step investment guide to buying this ETF.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian-owned.
The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire any financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms & Conditions and Financial Services Guide before using this website.
“Rask Invest” is considered a financial product and has a Product Disclosure Statement (PDS) and Target Market Determination (TMD), issued by InvestSMART. These documents can be accessed on the Rask Invest website. Please seek professional advice before making any investment decision with respect to Rask Invest.
© Rask Australia 2024